Brandon Jeffy

About Brandon Jeffy

Brandon D Jeffy, PhD, DABTI am a board certified Ph.D. toxicologist (DABT - Diplomate of the American Board of Toxicology) with more than 20 years of experience supporting pharmaceutical research and development from early discovery through late stage nonclinical and regulatory programs. My career spans discovery, investigative, and regulatory toxicology, with a focus on delivering strategic, science driven safety leadership across therapeutic areas and modalities. I have served as a senior toxicology partner on cross functional teams, shaping safety strategy, assessing and mitigating risk, and supporting informed decision making from target evaluation through IND enabling and advanced development stages.Regulatory ToxicologyI have extensive experience designing, overseeing, and interpreting nonclinical regulatory toxicology programs, including IND enabling and post IND studies across species and durations. My regulatory expertise includes genetic toxicology, safety pharmacology, general and chronic toxicology, and specialized programs such as DART, juvenile, and carcinogenicity assessments. I have authored nonclinical sections of regulatory submissions and briefing documents, supported interactions with global health authorities, and provided strategic input on regulatory pathways. I maintain deep familiarity with ICH and OECD guidelines, including contributing to the development of ICH M7 guidance.Discovery and Investigative ToxicologyMy discovery and investigative toxicology experience emphasizes mechanistic understanding and translational risk assessment to derisk safety liabilities early and throughout development. I have led investigative efforts to characterize target and compound related safety findings using in vitro, in vivo, computational, and biomarker based approaches. This includes expertise in molecular and cellular toxicology, toxicogenomics, safety biomarker development, and in silico prediction strategies, as well as participation in external toxicology consortia to integrate emerging science into practical decision making.Leadership and ManagementI bring substantial leadership and people management experience across toxicology organizations. This includes line and group management of scientists, oversight of toxicology operations, and responsibility for outsourced study strategy and execution. I have built and led high performing teams, mentored scientific staff, and contributed to organizational planning and capability development while maintaining a collaborative, accountable leadership approach.

Experience

1. Senior Director Group Leader, Nonclinical Safety and Toxicology

   Crinetics Pharmaceuticals

   Aug 2024 — Present · San Diego, CA, US

Education

• University of Arizona

  B.A., Ph.D., Cancer Biology/Pharmacology/Toxicology

  1990 — 2003

• The American Board of Toxicology

  DABT

  2011

Skills

• Genotoxicity
• Dabt
• Cyp Inhibition
• Genomics
• Cell Biology
• Dmpk
• Cell
• Pharmaceutical Industry
• In Vivo
• Ich Guidance
• Drug Development
• Ddi
• Assay Development
• Neuroscience
• Management of Direct Reports
• Elisa
• Glp
• Tissue Culture
• Pharmaceuticals
• Regulatory Toxicology
• Toxicokinetics
• Cell Based Assays
• Translational Medicine
• Pharmacology
• Cell Culture
• Bioinformatics
• R&D
• Molecular Biology
• Oncology
• Rodent Models
• In Vitro
• Drug Metabolism
• Epigenetics
• Drug Discovery
• Computational Toxicology
• In Silico
• Molecular Toxicology
• Investigative Toxicology
• Validation
• Animal Models